U2AF1 and myelodysplastic syndrome: In the 5 evaluable AML patients with spliceosome mutations, 40% reached CR/CRh (1 CR, 1 CRh)In the 7 spliceosome-mutated high risk-MDS patients, 57% reached marrow CRAmong the 29 patients without SF3B1/U2AF1/FLT3 mutations, 1 reached CR and 2 PR